New agent draws a bead on colorectal cancer

Article

The FDA recently approved cetuximab (Erbitux, ImClone Systems) for use in combination with irinotecan (Camptosar, Pfizer) for the treatment of epidermal growth factor receptor-1 (EGFR-1)-expressing, metastatic CRC in patients who are refractory to irinotecan-based chemotherapy. Cetuximab was also approved for use as monotherapy for the treatment of EGFR-1-expressing, metastatic CRC in those who are intolerant of irinotecan-based chemotherapy.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

© 2025 MJH Life Sciences

All rights reserved.